News | August 02, 2011

Feds Support Development of Drugs to Treat Radiation Injury

August 2, 2011 – The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). Many of the products BARDA is developing may find uses outside emergency medicine, such as treating complications that arise during radiation therapy for cancer.

The contracts are part of an ongoing effort to develop diagnostic tools and drugs to protect health and save lives in a radiological or nuclear emergency such as a nuclear bomb or improvised nuclear device. When the GI tract is exposed to high levels of radiation, it becomes inflamed, and the drugs being studied under these contracts may prevent or decrease that inflammation.

“Radiation injury to the GI tract is highly debilitating and potentially lethal,” said BARDA Director Robin Robinson, M.D. “The early-stage results with these two anti-inflammatory agents are very encouraging, and the additional studies we’re funding will determine whether these drugs have real promise as radiation countermeasures. Our ultimate goal is to develop safe and effective human therapeutics that could be used against acute radiation syndrome.”

Under a two-year, $2 million contract, Apogee Biotechnology Corp. of Hummelstown, Penn., will conduct preliminary studies of a drug known as ABC294640 to evaluate the drug’s efficacy in reducing gastrointestinal injury caused by radiation exposure. The drug works by inhibiting an enzyme called sphingosine kinase. ABC294640 has anti-inflammatory properties and can be taken orally.

The two-year, $2.9 million contract with Avaxia Biologics of Wayland, Mass., supports preliminary efficacy studies for Avaxia’s product, AVX-470. AVX-470 inhibits the effects of a protein called tumor necrosis factor, which increases inflammation. AVX-470 was initially developed to treat inflammatory bowel disease such as Crohn’s disease or ulcerative colitis.

Both contracts fund studies to show if the drugs are effective when administered 24 or more hours after radiation exposure. The studies are the next step in the drug development process and are needed before proceeding to clinical trials and pivotal efficacy studies.

Recognizing that health care providers will need a variety of effective ways to identify and treat the wide range of illnesses and injuries that can be caused by radiological and nuclear incidents, BARDA maintains a robust portfolio of advanced development projects focused on treating radiation-induced bone marrow, lung and skin injuries. BARDA also supports development of medicines to treat radiation-combined injury, in which radiation is combined with burns, blast injury or other trauma. Radiation-combined injury may occur in a nuclear denotation.

BARDA is seeking additional proposals for products that potentially could treat illness and injury from acute radiation syndrome, as well as improved diagnostic tools to measure the radiation dose a person has absorbed after a nuclear detonation or radiation accident. Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at www.fbo.gov.

BARDA, an agency within the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, provides a comprehensive integrated portfolio approach to the advanced research and development, innovation, acquisition and manufacturing infrastructure for vaccines, drugs, therapeutics, diagnostic tools and non-pharmaceutical products for public health emergency threats. These threats include chemical, biological, radiological and nuclear threats; pandemic influenza; and emerging infectious diseases.

For more information: www.phe.gov

 

Related Content

ASTRO and ASCO Launch New Cancer Care Quality Registry
News | Radiation Therapy | January 22, 2018
January 22, 2018 — A registry that tracks the quality of medical care provided to patients receiving cancer treatment
First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
Overlay Init